Neumora Therapeutics (NMRA) announced that effective February 14, 2025, Paul Berns, Neumora’s co-founder and executive chair of the Board of Directors, will transition to chief executive officer and chairman of the Board, and Henry Gosebruch will be leaving the Company. Additionally, Joshua Pinto, Ph.D., will serve as president, Bill Aurora, Pharm.D., will serve as chief operating and development officer, and Michael Milligan will serve as chief financial officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Levi & Korsinsky LLP Reminds Shareholders of a Lead Plaintiff Deadline of April 07, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA
- Largest borrow rate increases among liquid names
- Neumora Therapeutics Highlights Progress at Healthcare Conference
- Neumora Therapeutics price target lowered to $7 from $22 at BofA
- Neumora shares look oversold after 80% drop, says Mizuho